成纤维细胞生长因子21对小鼠肝纤维化的作用及其机制

王大秀; 韩继武

doi:10.3969/j.issn.1001-5256.2018.06.017

成纤维细胞生长因子21对小鼠肝纤维化的作用及其机制

DOI: 10.3969/j.issn.1001-5256.2018.06.017

哈尔滨医科大学附属第四医院消化内科

详细信息

中图分类号: R575.2
计量
- 文章访问数: 2040
- HTML全文浏览量: 25
- PDF下载量: 363
- 被引次数: 0
出版历程
- 收稿日期: 2017-11-13
- 出版日期: 2018-06-20

Effect of fibroblast growth factor 21 on hepatic fibrosis in mice and its mechanism

Department of Gastroenterology, The Fourth Affiliated Hospital of Harbin Medical University

摘要

摘要: 目的探索成纤维细胞生长因子（FGF）21对小鼠肝纤维化的作用及机制。方法将40只雄性ICR小鼠随机分为对照组（n=10）、模型组（CCl4处理）（n=15）、治疗组（CCl4+1.0 mg/kg FGF21处理）（n=15）。连续处理36 d后取血清及肝组织。检测ALT、AST、ALP、TBil、IL-6、IL-1β、TNFα水平;Masson染色观察病理改变;4-羟脯氨酸（4-Hyp）试剂盒检测肝内4-Hyp水平;real-time PCR检测肝胶原蛋白Ⅰ（CollagenⅠ）、α-平滑肌肌动蛋白（α-SMA）、TGFβ、IL-6、IL-1β、TNFαmRNA水平。计量资料多组间比较采用单因素方差分析,进一步两两比较采用LSD-t检验。结果 Masson染色结果显示,模型组肝纤维化程度较对照组明显加重,治疗组肝纤维化程度较模型组明显减轻;生化检测结果显示,模型组小鼠血清ALT、AST、ALP、TBil水平明显高于对照组,差异均有统计学意义（P值均<0.05）;治疗组小鼠血清ALT、AST、ALP、TBil水平较模型组明显下降,差异均有统计学意义（P值均<0.05）。血清E...
- 肝硬化 /
- 成纤维细胞生长因子21 /
- 细胞因子类 /
- 小鼠,近交ICR
Abstract: Objective To investigate the effect of fibroblast growth factor 21 (FGF21) on hepatic fibrosis in mice and the mechanism of its action. Methods Male ICR mice were randomly divided three groups: control group, model group (treated with CCl4) , and treatment group (treated with CCl4+ 1. 0 mg/kg FGF21) . All mice were sacrificed to collect serum and liver tissues after 36 consecutive days of treatment. Serum levels of alanine transaminase (ALT) , aspartate aminotransferase (AST) , alkaline phosphatase (ALP) , total bilirubin (TBil) , interleukin-6 (IL-6) , interleukin-1β (IL-1β) , and tumor necrosis factor-α (TNF-α) were measured. Liver pathological changes were analyzed by Masson staining. The hepatic 4-hydroxyproline (4-Hyp) level was measured using a hydroxyproline detection kit. The mRNA levels of hepatic collagen I, α-smooth muscle actin (α-SMA) , transforming growth factor-β (TGF-β) , IL-6, IL-1β, and TNF-α were determined by quantitative real-time PCR. Comparison between multiple groups was made by one-way analysis of variance, and comparison between any two groups weas made using the LSD-t test. Results The Masson staining showed that the model group had a significantly higher degree of hepatic fibrosis than the control group, and the treatment group had a significantly lower degree of hepatic fibrosis than the model group. The model group had significantly higher serum levels of ALT, AST, ALP, and TBil (all P < 0. 05) , and the treatment group showed significant reductions in the above parameters compared with the model group (all P < 0. 05) . Enzyme-linked immunosorbent assay indicated that the model group had significantly higher serum levels of IL-1β, IL-6, and TNF-α than the control group (all P < 0. 05) , and the treatment group showed significant reductions in the above parameters compared with the model group (all P < 0. 05) . The hepatic 4-Hyp level and mRNA levels of collagen I and α-SMA were significantly higher in the model group than in the control group (P = 0. 04, < 0. 001, and < 0. 001) , and they were significantly lower in the treatment group than in the model group (P = 0. 005, < 0. 001, and < 0. 001) . The hepatic mRNA levels of TGF-β, IL-6, IL-1β, and TNF-α were significantly higher in the model group than in the control group (all P < 0. 001) , and they were significantly lower in the treatment group than in the control group (all P < 0. 001) . Conclusion FGF21 attenuates hepatic fibrogenesis in mice, possibly by inhibiting the expression of TGF-β, IL-6, IL-1β, and TNF-α in the liver.
- liver cirrhosis /
- fibroblast growth factor 21 /
- cytokines /
- mice, inbred ICR

HTML全文

参考文献(21)

[1]BATALLER R, BRENNER DA.Liver fibrosis[J].J Clin Invest, 2005, 115 (2) :209-218.

[2]TSUKADA S, PARSONS CJ, RIPPE RA.Mechanisms of liver fibrosis[J].Clin Chim Acta, 2006, 364 (1-2) :33-60.

[3]FRIEDMAN SL.Stellate cells:A moving target in hepatic fibrogenesis[J].Hepatology, 2004, 40 (5) :1041-1043.

[4]WALLACE MC, FRIEDMAN SL, MANN DA.Emerging and disease-specific mechanisms of hepatic stellate cell activation[J].Semin Liver Dis, 2015, 35 (2) :107-118.

[5]NAGAKI M, MORIWAKI H.Implication of cytokines:Roles of tumor necrosis factor-alpha in liver injury[J].Hepatol Res, 2008, 38 (Suppl 1) :s19-s28.

[6]BERASAIN C, CASTILLO J, PERUGORRIA MJ, et al.Inflammation and liver cancer:New molecular links[J].Ann N Y Acid Sci, 2009, 1155 (1) :206-221.

[7]ZHANG W, JIA JD.Pathogenesis and new therapeutic targets of liver fibrosis[J].J Clin Hepatol, 2017, 33 (3) :409-412. (in Chinese) 张伟, 贾继东.肝纤维化的发病机制及治疗新靶点[J].临床肝胆病杂志, 2017, 33 (3) :409-412.

[8]PENG Q, ZHAO SJ, LI W.Research advances in signaling pathways involved in the development of hepatic fibrosis[J].J Clin Hepatol, 2017, 33 (5) :954-958. (in Chinese) 彭琴, 赵绅君, 李武.肝纤维化相关信号转导通路研究进展[J].临床肝胆病杂志, 2017, 33 (5) :954-958.

[9]MARKAN KR, NABER MC, AMEKA MK, et al.Circulating FGF21 is liver derived and enhances glucose uptake during refeeding and overfeeding[J].Diabetes, 2014, 63 (12) :4057-4063.

[10]DEGIROLAMO C, SABBA C, MOSCHETTA A.Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23[J].Nat Rev Drug Discov, 2016, 15 (1) :51-69.

[11]YU Y, BAI F, LIU Y, et al.Fibroblast growth factor (FGF21) protects mouse liver against D-galactose-induced oxidative stress and apoptosis via activating Nrf2 and PI3K/Akt pathways[J].Mol Cell Biochem, 2015, 403 (1-2) :287-299.

[12]REN GP, JIANG YY, LIU MY, et al.Utilization of SUMO expression vector to efficiently express mouse FGF-21 and studying of its bioactivity[J].J Northeast Agric Univ, 2009, 40 (5) :62-67. (in Chinese) 任桂萍, 姜媛媛, 刘铭瑶, 等.SUMO融合系统高效表达可溶性鼠源FGF-21及其活性的研究[J].东北农业大学学报, 2009, 40 (5) :62-67.

[13]XU P, YE X, ZHANG Y, et al.Long-acting hypoglycemic effects of PEGylated FGF21 and insulin glargine in mice with type 1 diabetes[J].J Diabetes Complicetions, 2015, 29 (1) :5-12.

[14]XU J, LLOYD DJ, HALE C, et al.Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice[J].Diabetes, 2009, 58 (1) :250-259.

[15]CAMPOREZ JP, JORNAYVAZ FR, LEE HY, et al.Cellular mechanism by which estradio protects female ovariectomized mice from high-fat diet-induced hepatic and muscle insulin resistence[J].Endocrinology, 2013, 154 (3) :1021-1028.

[16]YE D, WANG Y, LI H, et al.FGF21 protects against acetaminophen-induced hepatotoxicity by potentiating PGC-1alpha-mediated antioxidant capacity in mice[J].Hepatology, 2014, 60 (3) :977-989.

[17]XU P, ZHANG Y, WANG W, et al.Long-term administration of fibroblast growth factor 21 prevents chemically-induced hepatocarcinogenesis in mice[J].Dig Dis Sci, 2015, 60 (10) :3032-3043.

[18]LIU Y, ZHAO C, XIAO J, et al.Fibroblast growth factor 21 deficiency exacerbates chronic alcohol-induced hepatic steatosis and injury[J].Sci Rep, 2016, 6:31026.

[19]YANG C, LU W, LIN T, et al.Activation of liver FGF21 in hepatocarcinogenesis and during hepatic stress[J].BMC Gastroetero, 2013, 13:67.

[20]DUSHAY, CHUI PC, GOPALAKRISHNAN GS, et al.Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease[J].Gastroenterology, 2010, 139 (2) :456-463.

[21]COSKUN T, BINA HA, SCHNEIDER MA, et al.Fibroblast growth factor 21 corrects obesity in mice[J].Endocrinnology, 2008, 149 (12) :6018-6027.

施引文献

资源附件(0)

访问统计